← Leaderboards
Kim Erika Nichols
Childrens Hospital Of Philadelphia
$5,201,831
Attributed
$6,055,177
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,055,177 · 5
By mechanism
R01$4,613,552 · 2
R21$1,441,625 · 3
Top collaborators
- Jun J. Yang2 shared
Others in their field
Top investigators on “Defect”
- Lawrence Corey · Fred Hutchinson Cancer Center$207,121,712
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$110,264,229
- William George Nelson · Johns Hopkins University$80,153,436
- John A Tainer · Scripps Research Institute$73,493,996
- Stacey Gabriel · Massachusetts Institute Of Technology$48,168,194
- Steven G. Self · Fred Hutchinson Cancer Research Center$43,947,468
Research focus
DefectCellsPathogenesisInsightIn VitroGeneticIn VivoPredispositionInheritedProgenitorBiological ModelsMalignant NeoplasmsPhenotypePathway InteractionsGenesProductionT-LymphocyteInfectionViralLymphocytic Choriomeningitis VirusBaseCytokineProteinsImmunologic Deficiency Syndromes
Grant awards (16)
Pathogenesis of ETV6-Related Acute Lymphoblastic Leukemia$234,743
R01 · FY2025 · CA · contact PI
Targeting the immunoproteasome as a novel therapeutic strategy for hemophagocytic lymphohistiocytosis$227,500
R21 · FY2024 · AI · contact PI
Pathogenesis of ETV6-Related Acute Lymphoblastic Leukemia$194,227
R01 · FY2024 · CA · contact PI
Pathogenesis of ETV6-Related Acute Lymphoblastic Leukemia$420,390
R01 · FY2023 · CA · contact PI
Targeting the immunoproteasome as a novel therapeutic strategy for hemophagocytic lymphohistiocytosis$273,000
R21 · FY2023 · AI · contact PI
Pathogenesis of ETV6-Related Acute Lymphoblastic Leukemia$1,506,693
R01 · FY2020 · CA · contact PI
Pathogenesis of ETV6-Related Acute Lymphoblastic Leukemia$199,999
R01 · FY2020 · CA · contact PI
JAK inhibition as a novel treatment for hemophagocytic lymphohistiocytosis$178,000
R21 · FY2015 · AI · contact PI
JAK inhibition as a novel treatment for hemophagocytic lymphohistiocytosis$311,500
R21 · FY2014 · AI · contact PI
Role of SAP,SLAM and Fyn in NKT Cell Ontogeny and Activation$411,250
R01 · FY2012 · HL · contact PI
Role of SAP,SLAM and Fyn in NKT Cell Ontogeny and Activation$411,250
R01 · FY2010 · HL · contact PI
Role of SAP,SLAM and Fyn in NKT Cell Ontogeny and Activation$411,250
R01 · FY2009 · HL · contact PI
Role of SAP,SLAM and Fyn in NKT Cell Ontogeny and Activation$411,250
R01 · FY2008 · HL · contact PI
Role of SAP,SLAM and Fyn in NKT Cell Ontogeny and Activation$412,500
R01 · FY2007 · HL · contact PI
ROLE OF SH2D1A/SAP IN NKT CELL DEVELOPMENT AND FUNCTION$202,625
R21 · FY2006 · HL · contact PI
ROLE OF SH2D1A/SAP IN NKT CELL DEVELOPMENT AND FUNCTION$249,000
R21 · FY2005 · HL